The DEA is moving at a pace that could make a sloth look hyperactive when it comes to marijuana rescheduling. Nearly a year after an appeal questioning the agency’s handling of cannabis’ legal status was filed, the process is still… pending. No updates, no schedules, just a lot of bureaucratic waiting.
Last year, the DEA promised that reviewing marijuana’s classification would be a top priority. Clearly, “top priority” is a relative term. Even a presidential nudge hasn’t sped things up, as the agency continues to shuffle papers rather than make decisions. Meanwhile, opponents of rescheduling are gearing up for a fight, showing that cannabis reform isn’t just a legal matter—it’s a slow-motion tug-of-war.
Rescheduling marijuana wouldn’t make it fully legal, but it would officially recognize its medical value, ease research restrictions, and allow businesses to claim certain tax benefits. For now, though, advocates and patients are stuck in bureaucratic limbo, watching as federal agencies take their sweet time deciding what millions of Americans have already decided for themselves.
In the meantime, the DEA is quietly approving production for other controlled substances and psychedelics, proving that when it comes to some plants, the agency doesn’t hit snooze—but for marijuana, it seems the nap button is firmly pressed.
Dabbin-Dad Newsroom
